TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: In celiac disease (CeD), gluten induces immune activation, leading to enteropathy. TAK-101, gluten protein (gliadin) encapsulated in negatively charged poly(dl-lactide-co-glycolic acid) nanoparticles, is designed to induce gluten-specific tolerance. METHODS: TAK-101 was evaluated in phase 1 dose escalation safety and phase 2a double-blind, randomized, placebo-controlled studies. Primary endpoints included pharmacokinetics, safety, and tolerability of TAK-101 (phase 1) and change from baseline in circulating gliadinspecific interferon-γ–producing cells at day 6 of gluten challenge, in patients with CeD (phase 2a). Secondary endpoints in the phase 2a study included changes from baseline in enteropathy (villus height to crypt depth ratio [Vh:Cd]), and frequency of intestinal intraepithelial lymphocytes and peripheral gut-homing T cells. RESULTS: In phase 2a, 33 randomized patients completed the 14-day gluten challenge. TAK-101 induced an 88% reduction in change from baseline in interferon-γ spot-forming units vs placebo (2.01 vs 17.58, P = .006). Vh:Cd deteriorated in the placebo group (−0.63, P = .002), but not in the TAK-101 group (−0.18, P = .110), although the intergroup change from baseline was not significant (P = .08). Intraepithelial lymphocyte numbers remained equal. TAK-101 reduced changes in circulating α4β7+CD4+ (0.26 vs 1.05, P = .032), αEβ7+CD8+ (0.69 vs 3.64, P = .003), and γδ (0.15 vs 1.59, P = .010) effector memory T cells. TAK-101 (up to 8 mg/kg) induced no clinically meaningful changes in vital signs or routine clinical laboratory evaluations. No serious adverse events occurred. CONCLUSIONS: TAK-101 was well tolerated and prevented gluten-induced immune activation in CeD. The findings from the present clinical trial suggest that antigen-specific tolerance was induced and represent a novel approach translatable to other immune-mediated diseases. ClinicalTrials.gov identifiers: NCT03486990 and NCT03738475.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis
Singh, P., Arora, A., Strand, T. A., Leffler, D. A., Catassi, C., Green, P. H., Kelly, C. P., Ahuja, V., & Makharia, G. K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.06.037 · Cited by 1,743
Self-citationBandura, D. R., Baranov, V. I., Ornatsky, O. I., Antonov, A., Kinach, R., Lou, X., Pavlov, S., Vorobiev, S., Dick, J. E., & Tanner, S. D. (2009) · Analytical Chemistry · doi:10.1021/ac901049w · Cited by 1,295
Lebwohl, B., Sanders, D. S., & Green, P. H. R. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31796-8 · Cited by 1,065
Therapeutic Inflammatory Monocyte Modulation Using Immune-Modifying Microparticles
Getts, D. R., Terry, R. L., Getts, M. T., Deffrasnes, C., Müller, M., van Vreden, C., Ashhurst, T. M., Chami, B., McCarthy, D., Wu, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007563 · Cited by 378
Self-citation
Cited by
Catassi, C., Verdu, E. F., Bai, J. C., & Lionetti, E. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00794-2 · Cited by 475
Kondapalli, A. V., & Walker, M. D. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000561 · Cited by 25
Treatment of Primary Biliary Cholangitis
Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.012 · Cited by 9
Metadata
- Authors
- Kelly, C. P., Murray, J. A., Leffler, D. A., Getts, D. R., Bledsoe, A. C., Smithson, G., First, M. R., Morris, A., Boyne, M., Elhofy, A., Wu, T.-T., Podojil, J. R., Miller, S. D., Fogel, R., Freitag, T. L., Gerber, M., Haynes, P. K., Koren, M., Matson, M., Meri, S., Oliphant, T. H., Rizzardi, B. E., Silvester, J., & Turner, M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 161
- Issue
- 1
- Pages
- 66-80.e8
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W3136361932
- Cited by
- 183
- References
- 6
- FWCI
- 23.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1053/j.gastro.2021.03.014
- The paper
- Kelly, C. P., Murray, J. A., Leffler, D. A., Getts, D. R., Bledsoe, A. C., Smithson, G., First, M. R., Morris, A., Boyne, M., Elhofy, A., Wu, T.-T., Podojil, J. R., Miller, S. D., Fogel, R., Freitag, T. L., Gerber, M., Haynes, P. K., Koren, M., Matson, M., . . . Turner, M. (2021). TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study. Gastroenterology. https://doi.org/10.1053/j.gastro.2021.03.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.